Aspira Pathlab & Diagnostics

Aspira Pathlab & Diagnostics Share Buybacks

Share Buybacks of Aspira Pathlab & Diagnostics (540788.BO) as of Nov 8, 2026.

Share Buybacks

0.00INR

Last updated:

Share Buybacks of Aspira Pathlab & Diagnostics is 2022 0.00 INR. Share Buybacks of Aspira Pathlab & Diagnostics was 2021 30.00 M INR. It decreases by % lower compared to the previous year.

The Aspira Pathlab & Diagnostics Share Buybacks history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Share Buybacks
Date
Share Buybacks
Jan 1, 2016
1,300.00 INR
Jan 1, 2017
50.03 M INR
Jan 1, 2018
0.00 INR
Jan 1, 2019
51.00 M INR
Jan 1, 2020
28.60 M INR
Jan 1, 2021
30.00 M INR
Jan 1, 2022
0.00 INR
The Aspira Pathlab & Diagnostics Share Buybacks history
YEARShare BuybacksYoY
0.00INR-100.00%
30.00 MINR+4.90%
28.60 MINR-43.92%
51.00 MINR—
0.00INR-100.00%
50.03 MINR+3.85 M%
1,300.00INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aspira Pathlab & Diagnostics Stock analysis

What does Aspira Pathlab & Diagnostics do? Aspira Pathlab & Diagnostics Ltd generates revenue through pathology investigation services, radiology investigation services, and health packages at its diagnostic centers in Mumbai. The company offers specialized tests such as the Shanti Screening Test, COVID-19 Antibody Test, and COVID-19 RT-PCR Test, which are part of its diagnostic services portfolio. Customers include individuals seeking health screenings, patients requiring medical diagnostics, and healthcare providers who refer clients to its facilities. The firm's services are segmented into pathology, radiology, and health packages, with a focus on high-demand tests like COVID-19 detection profiles. The company's revenue streams are derived from conducting various pathological investigations across branches like biochemistry, hematology, and microbiology. Its health packages and pathology tests, including the COVID-19 Detection Profile 1 and 2, cater to both individual and institutional clients. The firm operates within the healthcare sector, providing diagnostic solutions for patients and medical professionals in Mumbai, with a particular emphasis on pandemic-related testing services during the global health crisis. Aspira Pathlab & Diagnostics Ltd monetizes its diagnostic capabilities through a mix of routine pathology services and specialized health packages. The Shanti Screening Test and other COVID-19-related tests form a significant portion of its revenue, especially during periods of high demand for pandemic testing. The company serves a broad customer base, including individuals, clinics, and hospitals that rely on its diagnostic expertise for accurate medical assessments. Aspira Pathlab & Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aspira Pathlab & Diagnostics stock

On Eulerpool you can find the complete historical development of Share Buybacks Aspira Pathlab & Diagnostics since 2006 – with annual values, charts, and detailed analysis.

Share buybacks represent the cash spent repurchasing the company's own shares. Buybacks reduce shares outstanding and can increase EPS.

Share Buybacks's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Share Buybacks's Aspira Pathlab & Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Aspira Pathlab & Diagnostics

All Key Metrics — Aspira Pathlab & Diagnostics